|
Academic/Biomedical Research
News & Jobs
|
|
|
|
|
|
|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Company Profiles
Research Store
Research Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
PLoS By Category | Recent
PLoS Articles
|
|
Biochemistry - Biophysics - Biotechnology - Critical Care and Emergency Medicine - Immunology - Molecular Biology - Pathology - Physics - Physiology - Public Health and Epidemiology
|
ProteinSeq: High-Performance Proteomic Analyses by Proximity Ligation and Next Generation Sequencing
Published:
Thursday, September 29, 2011
Author:
Spyros Darmanis et al.
by Spyros Darmanis, Rachel Yuan Nong, Johan Vänelid, Agneta Siegbahn, Olle Ericsson, Simon Fredriksson, Christofer Bäcklin, Marta Gut, Simon Heath, Ivo Glynne Gut, Lars Wallentin, Mats G. Gustafsson, Masood Kamali-Moghaddam, Ulf Landegren
Despite intense interest, methods that provide enhanced sensitivity and specificity in parallel measurements of candidate protein biomarkers in numerous samples have been lacking. We present herein a multiplex proximity ligation assay with readout via realtime PCR or DNA sequencing (ProteinSeq). We demonstrate improved sensitivity over conventional sandwich assays for simultaneous analysis of sets of 35 proteins in 5 µl of blood plasma. Importantly, we observe a minimal tendency to increased background with multiplexing, compared to a sandwich assay, suggesting that higher levels of multiplexing are possible. We used ProteinSeq to analyze proteins in plasma samples from cardiovascular disease (CVD) patient cohorts and matched controls. Three proteins, namely P-selectin, Cystatin-B and Kallikrein-6, were identified as putative diagnostic biomarkers for CVD. The latter two have not been previously reported in the literature and their potential roles must be validated in larger patient cohorts. We conclude that ProteinSeq is promising for screening large numbers of proteins and samples while the technology can provide a much-needed platform for validation of diagnostic markers in biobank samples and in clinical use.
More...
|
|
|
 |
|
|
|
|
|
|
|
|